- Vasopressin Receptor Antagonist, Tolvaptan, for Treating Hyponatremia in Patients with Heart Failure
-
Kyung-Jin Kim
-
Cardiovasc Prev Pharmacother. 2021;3(1):10-14. Published online January 31, 2021
-
DOI: https://doi.org/10.36011/cpp.2021.3.e3
-
-
2,979
View
-
76
Download
-
1
Citations
-
 Abstract
 PDF
- Hyponatremia is common in hospital setting in patients with heart failure and is associated with increased morbidity and mortality. However, despite these complications, appropriate treatment strategies other than established therapies such as hypertonic saline, loop diuretics, and fluid restriction are limited. Tolvaptan, a vasopressin receptor antagonist, has aquaretic effects that excrete free water and dilutes urine, thereby increasing serum sodium concentration. This new approach might be a landmark in the treatment of hyponatremia as there is a lack of controlled studies in this field. However, regardless of the associated advantage, tolvaptan is recommended to be used for less than 30 days owing to the possibility of liver injury. This study is aimed to present the clinical use of tolvaptan for hyponatremia in patients with heart failure.
-
Citations
Citations to this article as recorded by  - The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis
Vireza Pratama, Jordan Budiono, Jarir At Thobari, Bambang Widyantoro, Vita Yanti Anggraeni, Lucia Kris Dinarti
Frontiers in Cardiovascular Medicine.2024;[Epub] CrossRef
|
